RenovoRx Files to Sell 6.96M Shares of Common Stock for Holders
Seeking AlphaApr 26 17:18 ET
Express News | RenovoRx Regains Nasdaq Compliance
Moomoo 24/7Apr 18 08:35 ET
Express News | RenovoRx Regains Compliance With Nasdaq Stockholders’ Equity Requirement
Moomoo 24/7Apr 18 08:30 ET
RenovoRx Regains Compliance With Nasdaq Stockholders' Equity Requirement
Shaun Bagai, Chief Executive Officer of RenovoRx, stated, "Regaining compliance with Nasdaq's listing requirements represents another critical achievement for RenovoRx.
Business WireApr 18 08:30 ET
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
Sub-study of the pivotal Phase III TIGeR-PaC clinical trial offers important data to potentially assist in optimization of TAMP therapy.
Business WireApr 16 08:30 ET
Express News | RenovoRx Inc : Alliance Global Partners Cuts Target Price to $3.5 From $4
Moomoo 24/7Apr 15 10:34 ET
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway Into 2026
RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the closing of its previously announced private placement of approximately $11.1 million in gross proceeds.
BusinesswireApr 15 08:00 ET
INKT, BROG and ETAO Among Mid-day Movers
Seeking AlphaApr 8 12:24 ET
RenovoRx Executes Definitive Subscription Agreement With Accredited Investors For $11.1M At Market Private Placement
Cash position now expected to fund current operating plan into 2026Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial through the second interim readout and toward
BenzingaApr 8 08:36 ET
RenovoRx Announces $11.1 Million at Market Private Placement
RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the execution of definitive subscription agreements with accredited investors for a private placement which is expected to result in gross proceeds of approximately $11.1 million to RenovoRx, before deducting offering expenses.
BusinesswireApr 8 08:30 ET
Affimed N.V., Hutchmed, Annexon Among Healthcare Movers
Seeking AlphaMar 14 10:00 ET
RenovoRx Promotes Leesa Gentry to Chief Clinical Officer
Seeking AlphaMar 8 16:33 ET
RenovoRx Announces Key Leadership Promotions
InvestingMar 8 16:26 ET
RenovoRx Struggles to Avoid Nasdaq Delisting Amid Leadership Changes
TipRanksFeb 24 10:15 ET
RenovoRx Secures Funding for Phase III Cancer Trial
InvestingFeb 6 09:28 ET
RenovoRx Initiated at Buy by Alliance Global Partners
RenovoRx Initiated at Buy by Alliance Global Partners
Dow JonesFeb 2 08:14 ET
Express News | Alliance Global Partners Initiates Coverage On RenovoRx With Buy Rating, Announces Price Target of $4
Moomoo 24/7Feb 2 08:04 ET
RenovoRx Closes $6.1M Private Placement
Seeking AlphaJan 29 08:46 ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersSana Biotechnology (NASDAQ:SANA) shares increased by 45.2% to $7.49 during Wednesday's regular session. The company's market cap stands at $1.4 billion. Amarin Corp (NASDAQ:AMRN) stock increase
BenzingaJan 10 12:31 ET
Esperion Therapeutics, Voyager Therapeutics Among Healthcare Movers
Seeking AlphaJan 3 10:00 ET
No Data
No Data